NCCN Guidelines® Insights - Head and Neck Cancers, Version 2.2017

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the head and neck (H&N), and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel’s discussion and most recent recommendations regarding the increase in human papillomavirus–associated oropharyngeal cancer and the availability of immunotherapy agents for treatment of patients with recurrent or metastatic H&N cancer.

Target Audience

This activity is designed to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to the NCCN Guidelines for Head and Neck Cancers
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Head and Neck Cancers
Additional information
Supporters: 

This activity is supported by educational grants from Astellas, AstraZeneca, Celldex Therapeutics, Clovis Oncology, Genomic Health, Inc., Kyowa Hakko Kirin, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, and NOVOCURE. This activity is supported by an independent educational grant from Merck Co., Inc.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
06/10/2017
Course expires: 
06/10/2018
Cost:
$0.00

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

EDITOR:
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.

JNCCN:
Kimberly Callan, MS, Senior Director, Professional and Patient Publications, NCCN, has disclosed that she has no relevant financial relationships.
Genevieve Hartzman, MA, Journal Production Specialist, NCCN, has disclosed that she has no relevant financial relationships.

CE PLANNERS:
Deborah J. Moonan, RN, BSN, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships. (Employed by NCCN until 2/17/17)
Karen Kanefield, Manager, Continuing Education Accreditation and Program Operations, has disclosed that she has no relevant financial relationships.
Kathy Smith, Manager, CE Grant Writing & Project Management, NCCN, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Director, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.

INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
David Adelstein, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Maura L. Gillison, MD, PhD, Panel Member, has disclosed that she receives grant/research from Bristol-Myers Squibb Company, AstraZeneca Pharmaceuticals LP, Merck & Co., Inc., and Kyowa Hakko Kirin Co., Ltd.; and she received consulting fees/honoraria from Amgen Inc., Bristol-Myers Squibb Company, AstraZeneca Pharmaceuticals LP, Merck & Co., Inc., Celgene Corporation, and Eli Lilly and Company.
David G. Pfister, MD, Panel Chair, has disclosed that he received consulting fees/honoraria from Boehringer Ingelheim GmbH, and that he has received grant/research support from AstraZeneca Pharmaceuticals LP, Bayer HealthCare, Eli Lilly and Company, Exelixis Inc., Genentech, Inc., GlaxoSmithKline, MedImmune Inc., Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.
Sharon Spencer, MD, Panel Vice-Chair, has disclosed that she has no relevant financial relationships.
Douglas Adkins, MD, Panel Member, has disclosed that he has received grant/research support from Pfizer Inc., Celgene Corporation, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.
Barbara Burtness, MD, Panel Member, has disclosed that she has received grant/research support from Advaxis, Inc., Merck & Co., Inc., and Bristol-Myers Squibb Company; received consulting fees/honoraria from Amgen Inc., Debiopharm International S.A., Celgene Corporation, and AstraZeneca Pharmaceuticals LP; and served as a scientific advisor for Boehringer Ingelheim GmbH, MedImmune Inc., and VentiRx Pharmaceuticals, Inc.
A. Dimitrios Colevas, MD, Panel Member, has disclosed that he received consulting fees/honoraria and other financial benefit from Pfizer Inc., and that he received grant/research support from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Innate Pharma S.A., IRX Therapeutics, Inc., and Threshold Pharmaceuticals.
Robert L. Foote, MD, Panel Member, has disclosed that he received royalty income from Bionix, Elsevier, and UpToDate.
Robert I. Haddad, MD, Panel Member, has disclosed that he received grant/research support from Bristol-Myers Squibb Company, Merck & Co., Inc., AstraZeneca Pharmaceuticals LP, and Celgene Corporation; and that he received consulting fees/honoraria from Bristol-Myers Squibb Company, Merck & Co., Inc., AstraZeneca Pharmaceuticals LP, Pfizer Inc., Celgene Corporation, and Eisai Inc.
Antonio Jimeno, MD, PhD, Panel Member, has disclosed that he has served as a scientific advisor for AstraZeneca Pharmaceuticals LP.
William M. Lydiatt, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Bharat B. Mittal, MD, Panel Member, has disclosed that he has no relevant financial relationships.
John A. Ridge, MD, PhD, Panel Member, has disclosed that he has no relevant financial relationships.
Cristina P. Rodriguez, MD, Panel Member, has disclosed that she received grant/research support from Merck & Co., Inc.
Jatin P. Shah, MD, PhD, Panel Member, has disclosed that he served as a scientific advisor for and received consulting fees/honoraria from Proteocyte Diagnostics Inc.
Randal S. Weber, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Sue S. Yom, MD, PhD, Panel Member, has disclosed that she has served as a scientific advisor for Eli Lilly and Company; received royalty income from Springer and UpToDate;
received other financial benefit from Merck & Co., Inc.; and received grant/research support from Genentech, Inc., and BioMimetix Pharmaceutical, Inc.
Jennifer L. Burns, Guidelines Coordinator, NCCN, has disclosed that she has no relevant financial relationships.
Susan D. Darlow, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-17-006-H01-P

All clinicians completing this activity will be issued a certificate of participation.

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Accreditation Period

Course opens: 
06/10/2017
Course expires: 
06/10/2018

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing